ZyVersa Therapeutics Investor Relations Material

ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company dedicated to developing innovative drugs for renal and inflammatory diseases with significant unmet medical needs. The company leverages advanced proprietary technologies to create first-in-class therapeutics. Its key product candidates include the Cholesterol Efflux Mediator VAR 200, which is being developed to remove excess cholesterol from the kidneys' filtration system to prevent damage and reduce proteinuria, potentially treating conditions like diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome. Another major candidate is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit inflammation by targeting the ASC protein, which is implicated in a variety of inflammatory conditions, including neuroinflammatory diseases like Parkinson’s and Alzheimer’s, as well as metabolic complications related to obesity. The company is headquartered in Weston, Florida, and its shares are listed on the NASDAQ.